Does Depo-Provera Cause Brain Tumors? What the Medical Research Shows

What Is a Meningioma? More Than Just a "Benign" Tumor

To understand why the Depo-Provera research matters, you first need to understand what a meningioma is — and why the word "benign" does not tell the whole story.

Meningiomas arise from the meninges: the three-layered system of protective membranes that encase the brain and spinal cord. The outermost layer, the dura mater, is the tissue of origin for most meningiomas. Unlike glioblastomas or other tumors that arise from brain tissue itself, meningiomas grow from the coverings around the brain — which is part of why they are often called "extra-axial" tumors. They push on the brain from outside rather than arising within it.

Meningiomas are the most common primary brain tumor in adults, accounting for approximately 30% of all primary brain tumors according to the National Institutes of Health.^[3] That makes them more common than gliomas, pituitary tumors, or any other intracranial neoplasm. In the United States, roughly 33,000 new meningioma cases are diagnosed each year.

The WHO Grading System: Why Grade Matters

The World Health Organization classifies meningiomas into three grades based on cellular characteristics observed under a microscope:

Why "Benign" Is Often Misleading

The most important thing to understand about meningiomas is that their grade alone does not determine how dangerous they are. Location is equally critical — and in some cases more so.

A Grade I meningioma growing in the motor cortex, the optic nerve sheath, or the skull base near cranial nerves can be profoundly disabling — or even life-threatening — despite being technically "benign." Skull base meningiomas, which the BMJ 2024 study identified as particularly elevated in Depo-Provera users (specifically sphenoid wing meningiomas), are among the most challenging brain tumors to treat surgically. They grow adjacent to cranial nerves that control vision, hearing, facial sensation, swallowing, and eye movement. Damaging these structures during surgery to remove the tumor is not merely possible — it is a recognized surgical risk that neurosurgeons must balance against the risk of leaving tumor behind.

Surgery in these eloquent brain areas can result in permanent vision loss, hearing loss, facial palsy, swallowing difficulties, and other neurological deficits even when the operation is technically successful. This is why patients in the Depo-Provera litigation — many of whom have Grade I meningiomas — often report life-altering disabilities: the tumor's grade is benign, but the surgery required to remove it, and the tumor's location near critical brain structures, is anything but benign.

Demographics: Who Gets Meningiomas

Meningioma demographics are strikingly relevant to the Depo-Provera question. Women develop meningiomas at roughly twice the rate of men — a 2:1 female-to-male ratio that has intrigued researchers for decades and strongly implies a hormonal influence.^[3] Peak incidence occurs between the ages of 50 and 70, though meningiomas can develop at any age.

This demographic pattern is not coincidental. Meningiomas were known to express sex hormone receptors long before Depo-Provera came under scrutiny. The 2:1 sex ratio, combined with the fact that 60–80% of meningiomas express progesterone receptors, provides the foundational biological rationale for why a potent progestogen like medroxyprogesterone acetate could plausibly drive meningioma growth in susceptible women.

What Medroxyprogesterone Acetate Does in the Body

Depo-Provera's active ingredient is medroxyprogesterone acetate — MPA. To understand why this specific compound may be more problematic than other hormonal contraceptives, it helps to understand what MPA actually does at the molecular level.

MPA's Receptor Binding Profile

MPA is a synthetic progestogen — a manufactured molecule designed to mimic the effects of progesterone, the naturally occurring hormone produced by the ovaries. But MPA is not a perfect copy. It is a 17-alpha-hydroxyprogesterone derivative with several properties that distinguish it from natural progesterone and from the progestogens found in oral contraceptive pills.

Most significantly, MPA has exceptionally high binding affinity for progesterone receptors (PRs). When MPA binds to a progesterone receptor, it activates the same downstream signaling pathways that natural progesterone activates — triggering changes in gene expression, cell behavior, and tissue growth. In breast tissue and uterine tissue, these effects are well documented. In meningioma tissue, they appear to follow the same pattern.

MPA also has measurable activity at glucocorticoid receptors and, to a lesser degree, androgen receptors. The glucocorticoid activity suppresses the HPA axis (hypothalamic-pituitary-adrenal axis), which contributes to MPA's contraceptive mechanism by inhibiting ovulation. But it also means MPA is interacting with multiple hormonal systems simultaneously, with effects that are not fully characterized in all tissue types.

The PR-Positive Meningioma Connection

Here is where the biology becomes directly relevant to the safety question. Research has consistently shown that 60–80% of meningiomas express progesterone receptors at detectable levels.^[3] These are called PR-positive meningiomas. The remaining 20–40% either express progesterone receptors at very low levels or are classified as PR-negative.

The significance of PR-positivity in meningiomas is analogous to PR-positivity in breast cancer. In breast cancer, PR-positive tumors grow in response to progesterone stimulation — which is precisely why anti-hormonal therapies (like tamoxifen or aromatase inhibitors) are effective treatments for hormone-receptor-positive breast cancer. The therapy works by blocking the receptors or reducing hormone levels, thereby depriving the tumor of its growth signal.

PR-positive meningiomas appear to operate by the same mechanism. When progesterone — or in this case, MPA with its high PR binding affinity — binds to progesterone receptors on meningioma cells, it may stimulate tumor proliferation. The evidence for this comes from multiple directions: observational studies showing higher meningioma rates in women with greater progesterone exposure, the known regression of some meningiomas after anti-progestin treatment, and the basic in vitro research showing that progesterone stimulates meningioma cell growth in laboratory settings.

This biological mechanism — sometimes called the "hormone-responsive tumor" model — is the same framework that explains why women develop meningiomas at twice the rate of men, why some meningiomas enlarge during pregnancy (a period of very high progesterone levels), and why meningioma incidence does not parallel estrogen exposure patterns as cleanly as it parallels progesterone exposure.

Why Injectable MPA May Be More Problematic Than Oral Progestogens

Not all progestogens are created equal, and not all delivery systems create equal exposure. This distinction is central to understanding why studies have found Depo-Provera to carry elevated meningioma risk while other hormonal contraceptives — oral pills, patches, hormonal IUDs, and implants — have not shown the same association.

When you take an oral contraceptive pill, the progestogen it contains is absorbed from the gut, passes through the liver (first-pass hepatic metabolism), and enters the bloodstream in a modified, partially metabolized form. The level of the hormone rises after each daily pill and then falls before the next dose. This creates a cycling pattern rather than a sustained plateau. The liver metabolizes a significant fraction of the progestogen before it reaches target tissues. Most oral progestogens also have lower intrinsic binding affinity for progesterone receptors compared to MPA.

Depo-Provera CI works differently at every level of this process. First, it is administered by intramuscular injection, bypassing the gut and the first-pass hepatic metabolism entirely. The MPA is deposited in a crystalline depot within the muscle tissue, and it dissolves slowly over approximately 12 weeks, releasing MPA continuously into the bloodstream. There is no daily cycling — there is a sustained, continuously elevated MPA blood concentration for roughly three months per injection.

In women who use Depo-Provera for multiple years — say, four years or 16 consecutive injections — the progesterone receptors in any PR-positive meningioma cells would have been continuously exposed to sustained high-level MPA stimulation for that entire period. The biological rationale for why this could promote meningioma growth, in women who are biologically susceptible to PR-positive meningiomas, is well-supported by basic hormone biology.

The Four Studies: A Deep Dive into the Evidence

Scientific evidence for drug safety claims is only as strong as the studies that support it. What makes the Depo-Provera meningioma evidence unusually compelling is not any single study, but the fact that four independent research groups, using different study designs, different populations, different time periods, and different methodologies, all reached the same fundamental conclusion. This scientific convergence is the hallmark of a genuinely robust finding.

What the FDA Did — and What It Took

The FDA's meningioma warning for Depo-Provera did not emerge automatically from the scientific evidence. It was the product of a multi-year regulatory process with a pivotal reversal at its center — and understanding that process is important for understanding why the warning matters so much to the litigation.

The Timeline: From BMJ Study to FDA Label

The Exact FDA Warning Language

What the Warning Means: Regulatory Acknowledgment

The FDA does not add warnings to drug labels casually. The regulatory standard for adding a warning is that the available evidence supports a reasonable association between the drug and the adverse event — not certainty, not proof of causation in the strict sense, but a supported association that warrants informing healthcare providers and patients. The December 2025 approval of the meningioma warning therefore represents a federal regulatory conclusion that the available science supports the Depo-Provera meningioma link.

This has profound legal consequences. For months, Pfizer had argued that the FDA had implicitly endorsed the position that the link was too weak to warrant a warning — based on the 2024 rejection of their initial proposal. The December 2025 approval invalidated that narrative. Plaintiffs now argue that because the FDA ultimately agreed that a warning was warranted, Pfizer's earlier failure to provide adequate warning of the meningioma risk was a choice that harmed patients — not an FDA-mandated constraint.

For current and former Depo-Provera users, the FDA warning also carries practical significance: it tells healthcare providers to monitor long-term users for meningioma symptoms and to discontinue the drug if a meningioma is diagnosed. Women who are currently on Depo-Provera and have used it long-term should discuss the warning with their prescriber and ask about appropriate monitoring.

Risk by Duration: What Your Exposure History Means

One of the most consistent features of the Depo-Provera meningioma evidence is its duration-dependence. The risk is not uniform across all users — it appears to scale with the length of exposure. Here is what the research shows about risk at different levels of Depo-Provera use, based on the available evidence:

Does Risk Decrease After Stopping?

This is an important question the current evidence base does not fully answer. The available studies predominantly assess risk in active users or recent former users. Based on what is known about meningioma biology — that they grow slowly and may plateau without continued hormonal stimulation — there is theoretical reason to expect that risk of developing a new meningioma may not continue to increase indefinitely after stopping Depo-Provera. Some evidence from other progestogen-associated meningiomas (notably, meningiomas associated with cyproterone acetate) suggests that tumor growth can slow or stabilize after the offending progestogen is discontinued.

However, a meningioma that has already developed during Depo-Provera use does not simply disappear when Depo-Provera is stopped. Established meningiomas require management — surgical resection, radiosurgery, or watchful waiting with serial MRI — regardless of whether Depo-Provera use continues or ceases. The critical issue for women who used Depo-Provera long-term and have since stopped is whether a meningioma was silently developing during that period, which is why appropriate monitoring and medical evaluation is important even for former users who are now symptomatic.

Ongoing Scientific Questions: Causation vs. Correlation

An honest assessment of the evidence requires acknowledging what the studies do and do not establish. All four key studies are observational — meaning they analyzed real-world data from existing patient populations rather than randomly assigning women to receive Depo-Provera or a placebo. This is the nature of contraceptive research: a randomized controlled trial (RCT) to test whether Depo-Provera causes brain tumors is not ethically or practically feasible.

The critical scientific question is therefore: given that all studies are observational, how confident can we be that Depo-Provera is actually causing meningiomas, rather than merely correlating with them due to unmeasured factors?

The Confounding Challenge — and How Studies Addressed It

The primary methodological concern in observational studies is confounding: the possibility that some unmeasured third factor could explain both Depo-Provera use and meningioma risk. Each of the four studies used different strategies to address this concern.

The BMJ study matched cases and controls by age, geographic region, and healthcare utilization — ensuring that any age-related differences in meningioma risk did not confound the analysis. The UBC study compared Depo-Provera users specifically to other hormonal contraceptive users, eliminating the possibility that women who seek hormonal contraception differ systematically from those who do not. The TriNetX study was conducted using electronic health records from 68 healthcare systems, capturing diverse real-world populations across the United States.

No observational study can perfectly eliminate confounding. But the consistency of findings across studies with different confounding profiles is itself evidence against confounding as the primary explanation. If confounding were driving the association, you would expect the different study designs — with different control groups and different confounders — to produce inconsistent results. They do not.

The Bradford Hill Framework: How Strong Is the Causal Evidence?

Epidemiologists use the Bradford Hill criteria — a nine-factor framework developed in 1965 — to evaluate causal relationships from observational data. Applying these to the Depo-Provera meningioma evidence:

The evidence satisfies six of the nine Bradford Hill criteria robustly — an unusually strong showing for observational pharmaceutical safety research. The only major criterion not satisfied is experimental evidence from an RCT, which is not feasible in this setting. The overall causal evidence is substantially stronger than what is available for many drug safety claims that have generated mass tort litigation.

What Affected Women Should Ask Their Doctors

If you are a current or former long-term Depo-Provera user, the FDA warning and the underlying research are directly relevant to your healthcare. Here is what medical experts recommend discussing with your provider:

The Litigation: Where This Science Goes Next

The four studies described in this article are not just academic publications — they are the evidentiary foundation of active federal litigation involving thousands of women. Understanding the litigation context helps explain why the science is currently receiving so much attention and why a June 2026 courtroom hearing matters to the entire scientific record.

The MDL: 3,490 Cases and Counting

As of April 5, 2026, 3,490 cases are pending in In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, before Judge M. Casey Rodgers in the Northern District of Florida (Pensacola Division).^[2] The MDL was centralized in February 2025 and has grown at a rate of approximately 650 new cases per month.

The central legal claim is failure to warn: plaintiffs allege that Pfizer knew or should have known about the meningioma risk based on the biological plausibility and early epidemiological signals, and failed to warn healthcare providers and patients in time for them to make informed decisions about Depo-Provera use.

The Daubert Hearing: Science Goes Before the Court

The most significant near-term event for the litigation science is the Daubert general causation hearing scheduled for June 24–26, 2026 before Judge Rodgers. A Daubert hearing is the proceeding in which a federal judge evaluates the scientific reliability of expert witness testimony — specifically, whether plaintiffs' causation experts can present their opinions about the Depo-Provera meningioma link to a jury.

At the Daubert hearing, plaintiffs' scientific experts will present the BMJ study, UBC cohort, Cleveland Clinic analysis, and TriNetX data to Judge Rodgers, along with their interpretation of the biological mechanism. Pfizer's experts will challenge both the studies' methodologies and the causal inference drawn from them. The judge will then determine whether the plaintiffs' causation theory meets the legal standard for scientific reliability set forth in Daubert v. Merrell Dow Pharmaceuticals (1993).

A favorable Daubert ruling for plaintiffs — allowing their experts to testify — is widely expected to accelerate the litigation toward either settlements or trial. An adverse ruling would dramatically constrain plaintiffs' ability to prove causation and would benefit Pfizer significantly. The hearing represents, in a literal sense, the moment where the science contained in those four peer-reviewed studies goes before the court for judicial evaluation.

The first bellwether trial — Blonski v. Pfizer, scheduled for December 7–14, 2026 — will be the first time a jury hears the full science and renders a verdict. If the jury finds Pfizer liable, the verdict will send a powerful signal about how subsequent cases are likely to be valued and will almost certainly trigger serious settlement discussions. The combined pressure of 3,490 pending cases, the FDA warning, four corroborating studies, and the approaching trial creates enormous incentive for Pfizer to seek a negotiated resolution — though the timing and terms of any potential settlement remain unknown.

Frequently Asked Questions